The FDA has approved once-daily oral semaglutide 25 mg (Wegovy Pill, Novo Nordisk) as the first GLP-1 agonist pill for weight management. The new indication is “to reduce excess body weight and ...

The FDA has approved a pill form of the popular injectable obesity drug Wegovy. People on the highest dose dropped about 14 percent of their starting weight after 64 weeks, with a high number of super ...

Dec 8 (Reuters) - Structure Therapeutics (GPCR.O), opens new tab said on Monday its obesity pill showed weight loss of up to 11.3% after 36 weeks of treatment in a mid-stage study, driving the company ...

Anthony Joshua will have to make weight for the first time in his career later this month. One of the benefits of being a heavyweight is that you don’t have to boil down to a certain weight. However, ...

Wyze has just launched a new “Ultra Bodyscan” weight scale that works with Fitbit and Android Health Connect, but does a lot more than just take your weight. Wyze has a lineup of scale options priced ...

Hi, I'm Bill. I'm a software developer with a passion for making and electronics. I do a lot of things and here is where I document my learning in order to be able to inspire other people to make ...

People in the United States are obsessed with dieting and body size. That may be due to the fact that 40.3% of adults have obesity today, according to the US Centers for Disease Control and Prevention ...

A Reddit user has sparked a viral mystery after discovering a significant discrepancy in their weight when using two different smart scales—prompting a lively ...

Gautam Solar has unveiled its 630W R-Series TOPCon solar modules for utility-scale PV projects. The new modules are ALMM and BIS approved, ensuring compliance for government projects and large-scale ...

Oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity. In a ...

An international trial reveals that a 7.2 mg dose of semaglutide drives greater weight loss than the standard 2.4 mg, but raises questions about side effect trade-offs in obesity treatment. Study: ...

Viking Therapeutics has reported phase 2 data on its oral obesity drug candidate, linking the peptide to weight loss of up to 12.2% after 13 weeks. But, with 38% of patients discontinuing treatment at ...